AMAG dips then recovers on Swiss Rienso recall
This article was originally published in Scrip
AMAG Pharmaceuticals closed down 10.7% on 22 May after the company said one batch of its intravenous iron deficiency anemia (IDA) drug Rienso (ferumoxytol) was recalled in Switzerland following four adverse events related to hypersensitivity reactions, including one death.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.